
FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
May 14, 2019
LA JOLLA, CA The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed in the laboratory of Scripps Research Professor Luc Teyton, MD, PhD, and licensed to French pharmaceutical company Abivax.
The FDA approval allows Abivax testing of ABX196 in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. ABX196 showed potent efficacy against HCC in preclinical testing.
The translation of basic research discoveries to the clinic is the greatest achievement we can hope for as clinician scientists. says Teyton, who is also a member of Abivax's Scientific Advisory Board. The use of ABX196 in the context of immunotherapy has been shown to be beneficial in multiple animal models of cancer, but the results with hepatocellular carcinoma are spectacular. We are looking forward to impacting the disease in patients, especially given the limitations of current therapies.
The open IND allows Abivax to test ABX196 in combination with nivolumab (Opdivo, Bristol-Myers Squibb), a checkpoint inhibitor, in a first phase 1/2 clinical trial to treat patients with HCC. The initial dose-escalation phase of the study will be conducted at the Scripps MD Anderson Cancer Center in San Diego, California, USA; additional leading cancer centers in the U.S. will be involved in the subsequent expansion phase of the study. The first patient is expected to be enrolled this summer.
We are thrilled to have been given the green light by FDA for our U.S. study. says Hartmut J. Ehrlich, MD, chief executive officer of Abivax. This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned U.S. cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab. Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.
ABX196 is a synthetic glycolipid agonist of invariant natural killer T cells (iNKT) in a liposomal formulation. A phase 1 clinical trial conducted by Abivax in healthy volunteers has been completed and demonstrated safety and tolerability as well as a potent activation of iNKT cells. ABX196, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC. Abivax holds exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.
Despite the recent introduction of checkpoint inhibitors, hepatocellular carcinoma continues to be a substantial therapeutic challenge, as only about 20 percent of the treated patients show a response to these new drugs says Darren Sigal, MD, program director of GI Oncology at Scripps Clinic and Scripps MD Anderson Cancer Center in San Diego, and principal investigator of the study. While checkpoint inhibitors block a do not attack me' signal on cancer cells, ABX196 activates iNKT cells, a subpopulation of lymphocytes that is critical for mounting an effective immune response. The synergy between these two molecules carries substantial promise for improved outcomes for patients with this deadly cancer.
Checkpoint inhibitors like nivolumab are a leading class of therapeutic monoclonal antibodies that block certain endogenous proteins (PD-1/PDL-1) made by immune cells, such as T cells, as well as some cancer cells. These proteins effectively hijack the immune system, causing it to keep immune responses in check and preventing T cells from killing cancer cells. When these proteins are blocked, the brakes on the immune system are released and T cells are able to kill cancer cells much more efficiently. In some cancers, treatment with checkpoint inhibitors has been highly efficacious. However, due to the tumor micro-environment in other cancers, such as HCC, checkpoint inhibitors can have difficulties exerting their effects. ABX196 is intended as a drug that will potentiate the efficacy of checkpoint inhibitors by activating iNKT cells to kill tumor cells.
HCC is the most common form (75 to 90 percent) of primary liver cancer in adults. It typically occurs in the setting of chronic liver inflammation and/or cirrhosis and is closely linked to chronic viral infection such as hepatitis B or C, exposure to toxins such as alcohol, and to certain diseases such as non-alcoholic steatohepatitis (NASH).
The incidence of and deaths related to HCC are increasing in the United States and globally due to hepatitis B and C virus infections, as well as NASH. Prevalence data from 2018 show a total of 79,000 cases of HCC in the U.S. and G5 Europe (Germany, France, Italy, Spain and the UK), with 67,000 new cases, and a total of 260,000 cases in China with 338,000 new cases. Globally, there were 841,000 new cases of liver cancer (ranking it sixth of all reported cancers) and 782,000 fatalities (ranking it fourth) in 2018.
Currently, the American Cancer Society reports five-year survival rates in the U.S. of 31 percent for localized HCC, 11 percent for regional, and 2 percent for distant or metastatic, indicating a clear unmet medical need for improved therapies for HCC.
Cancer Immunology & Microbiology Teyton, Luc
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
02/05/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
01/05/2026
January 5 2026, 18:30 (PST) NBCUniversal's Peacock to Be First Streamer to ...
01/04/2026
January 4 2026, 18:00 (PST) DOLBY AND DOUYIN EMPOWER THE NEXT GENERATON OF CREATORS WITH DOLBY VISION
Douyin Users Can Now Create And Share Videos With Stun...
25/03/2026
L3Harris Technologies and RFTEQ Pty Ltd signed a memorandum of understanding to ...
25/03/2026
L3Harris delivers combat-ready Torpedo Tube Launch and Recovery system, which deploys and retrieves Iver4 900 autonomous underwater vehicles through submarine t...
25/03/2026
The company expands leadership team under Chief Revenue Officer Amilcar Perez
S...
25/03/2026
Winter Olympic Games Opening Ceremony features in top 10 programmes of the month...
25/03/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
25/03/2026
Providing wide view timing visibility across the entire production chain...
25/03/2026
Continuing development drives advances in security, availability, access and connectivity...
25/03/2026
Caudalie, the renowned French cosmetics brand, has unveiled a state-of-the-art 200-seat auditorium at its new headquarters in the historic Marais district of ce...
25/03/2026
Telestream, a global leader in media workflow technologies, today announced expanded integration with Adobe Premiere, Adobe Media Encoder (AME), and Frame.io, d...
25/03/2026
Marshall Electronics is expanding its lineup of high-performance POV cameras designed for broadcast, live production and professional AV applications with the d...
25/03/2026
OOONA, a global provider of professional management and production tools for the media localization industry, announced today that it has been awarded the TPN G...
25/03/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
25/03/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
25/03/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
25/03/2026
SipRadius, specialists in secure, low-latency media transport, will drive innovation and interoperability still further with the launch of the SipMX Alliance at...
25/03/2026
QuickLink, a leading provider of award-winning video production and remote contribution solutions, will showcase its award-winning StudioPro ecosystem at The 2...
25/03/2026
Alfalite, the only European manufacturer of LED screens, will once again be present at NAB Show, the leading global event for the broadcast, media and entertain...
25/03/2026
PC, a leading provider of integrated communication solutions, will make its NAB 2026 Show debut in Booth C 3341. The company will highlight the newly branded On...
25/03/2026
Open video transport network simplifies satellite transition with new partnerships and global reach as spectrum auction nears
LTN will demonstrate how its purp...
25/03/2026
Test & measurement innovator, Leader Electronics, will present the full range of Leader, PHABRIX and LeaderPhabrix T&M solutions at the NAB Show, which takes pl...
25/03/2026
MNC Software, a global leader in network management and operational support systems tailored to the broadcast and media industry, today announced the appointmen...
25/03/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
25/03/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
25/03/2026
Starfish highlights flexible TS Splicer releases and new Monitoring Dashboard at...
25/03/2026
XLNTSOUND Elevates Video Production with Blackmagic Design
Brie Clayton March 24, 2026
0 Comments
Audio company upgrades workflow with Blackmagic Cine...
25/03/2026
First Time Exhibitor IPC Introduces One Link Keypanels for One Connect Intercom ...
25/03/2026
Back to All News
Netflix Announces the Start of Production for Reasonable Doubts
Entertainment
25 March 2026
GlobalSpain
Link copied to clipboard
Download...
25/03/2026
Back to All News
2026 World Baseball Classic Becomes the Most-Watched Program ...
25/03/2026
NBC Sports Deploys viztrick AiDi to Stream Live Events in 9:16 Mobile-First Form...
25/03/2026
At the half-time whistle of the UEFA EURO 2020 round of 16 football match betwee...
24/03/2026
Utah Scientific to Showcase a Variety of Hybrid SDI/IP Innovations at the 2026 N...
24/03/2026
Mediaproxy will showcase an updated version of its LogPlayer interface at NAB Sh...
24/03/2026
C gep de Jonqui re, a public college in Qu bec, has upgraded its TV studio complex with five Calrec Brio consoles and a Dante IP network. The installation was c...
24/03/2026
The American Association of Professional Baseball (AAPB) has announced new and r...
24/03/2026
National Telecom Public Company Limited (NT) used Ateme's KYRION platform fo...
24/03/2026
Grass Valley has expanded its relationship with ImSoPROD, the TV production entity of FDJ United, with the deployment of LDX C98 compact cameras across its nati...
24/03/2026
The E.W. Scripps Company is launching Scripps Sports Network (SSN), a free, ad-s...
24/03/2026
NEP Group has launched NEP Platform, a new software orchestration system that un...
24/03/2026
Daktronics has partnered with the Arizona Diamondbacks to design, manufacture and install a new LED video display and three ribbon boards at Chase Field in Phoe...
24/03/2026
Grass Valley has completed an upgrade of University of Pittsburgh Athletics'...
24/03/2026
Daktronics is upgrading eight LED displays at Wrigley Field in Chicago, totaling more than 8,300 square feet, using the Daktronics Renew product line. The upgra...
24/03/2026
Advanced Systems Group has appointed Kevin Poole as Senior Project and Support Manager within the ASG Workflow and Tools practice. The position is newly created...
24/03/2026
In an increasingly streaming-centric world, protecting high-value live sports co...
24/03/2026
Mediaproxy will showcase an updated version of its LogPlayer interface at NAB Show, April 19-22 in Las Vegas, booth W1423. The update includes AI tools, native ...
24/03/2026
The production studio has worked with content juggernauts such as MrBeast, The R...